Volume 4 • Issue 1 • 2022

Case Report

Journal of Medical Research and Case Reports

A Case of Severe Type B Lactic Acidosis in a Patient with Acute Lymphoblastic Leukemia

Ami K. Patel* and Nancy Andrea

Department of Hematology/Oncology, Boston University Medical Center, Boston, MA, USA

***Corresponding Author:** Ami K. Patel MD, Department of Hematology/Oncology, Boston University Medical Center, Boston, MA, USA.

Received: March 14, 2022; **Published:** March 23, 2022

Abstract

The development of type B lactic acidosis related to hematologic malignancies is a rare phenomenon. The exact mechanism is not known but can result in death if not recognized and corrected. The mainstay of therapy remains systemic cancer-directed therapy to treat the underlying disease although intravenous bicarbonate and renal replacement therapy have been employed at times for acute treatment of severe lactic acidosis as a bridge until chemotherapy can be initiated. However, these therapies do not appear to have a long-term effect. In this care report, we present a 75-year-old-male with acute lymphoblastic leukemia who was admitted to the hematology/oncology service after routine labs drawn in clinic revealed a lactate dehydrogenase (LDH) level of 4554 U/L thought to be due to severe type B lactic acidosis portending poor prognosis. Prompt diagnosis and treatment of this rare complication of hematologic malignancies is critical in trying to prevent poor outcomes.

Keywords: *Severe Type B Lactic Acidosis; Acute Lymphoblastic Leukemia; Hematologic Malignancies; Lactate Dehydrogenase (LDH)*

Abbreviations: LDH: Lactate dehydrogenase; AML-M6b: Pure erythroid leukemia; ALL: Acute lymphoblastic leukemia; TNFα: Tumor necrosis factor alpha; NRTIs: Nucleoside reverse transcriptase inhibitors; HIV: Human immunodeficiency virus; Mg: Milligrams

Introduction

Type B lactic acidosis is a distinct form of metabolic acidosis characterized by low blood pH (normal=7.35-7.45) and the accumulation of lactate in the blood (blood concentration greater than or equal to 5 mmol/L) [1]. It is of particular interest because it is a rare and often lethal complication of hematological malignancies. Its exact mechanism is not well understood although several possible mechanisms have been proposed as discussed below in this case report. There appears to be some association with common diseases (i.e., diabetes), drugs, toxins, inborn errors in metabolism, and hereditary/miscellaneous disorders. In comparison, type A lactic acidosis which is much more common and has been more extensively studied usually results due to lack of oxygen from increased tissue hypoperfusion or acute severe hypoxemia. It leads to impaired cellular respiration which forces cells to metabolize glucose anaerobically and thus results in increased production of lactate. [2-3] In light of this, we present a 75-year-old-male with acute lymphoblastic leukemia who was admitted to the hematology/oncology service when he was sent to the emergency department after routine labs drawn in clinic revealed an LDH of 4554 U/L without other evidence of tumor lysis syndrome. His overall clinical

presentation was felt to be most consistent with severe type B lactic acidosis portending a poor prognosis.

Case Presentation

Our patient is a 75-year-old-male with acute lymphoblastic leukemia on palliative chemotherapy who was admitted to the hematology/oncology service after routine labs drawn in clinic revealed at LDH of 4554 U/L. At the time of presentation, he endorsed increased generalized weakness and fatigue over the past 2-3 weeks. He also reported decreased oral intake due to mouth pain for a couple of days prior to admission. At baseline, he had poor functional status and spent most of his time in bed. He had intermittent disorientation since his last cranial radiation treatment 5 months prior to admission.

Regarding his oncology history, the patient was initially diagnosed with AML-M6b via bone marrow biopsy 3.5 years prior to admission after initial presentation to his primary care physician for evaluation of extensive abdominal and extremity bruising. He underwent 7+3 induction chemotherapy with cytarabine and daunorubicin which was complicated by lower extremity edema and ascites that resolved without intervention. His blood counts improved to baseline post-chemotherapy and no further chemotherapy was pursued due to risk of neurotoxicity in an elderly patient. Patient was then in remission for nearly 1 year when he developed dyspepsia and dysphagia with solids and left eye ptosis related to 3rd nerve palsy. Gastric biopsies were consistent with ALL. Lumbar puncture and bone marrow biopsy confirmed ALL with central nervous system involvement after which ECOG E2993 Protocol: Phase I (vincristine/prednisone, intrathecal methotrexate, and daunorubicin) was initiated but was complicated by profound neutropenia and neuropathy. Phase II (cyclophosphamide, cytarabine, and 6-mercaptopurine) was initiated about a month later followed by 1 cycle of consolidation chemotherapy with cytarabine/etoposide but this was complicated by herpes zoster scalp infection. About 4 months later, maintenance therapy (prednisone, mercaptopurine, methotrexate, and vincristine) was initiated but patient subsequently developed double vision thought to be secondary to 6th nerve palsy after about 3 months of treatment. Lumbar puncture confirmed recurrence of malignant cells in the cerebrospinal fluid despite treatment with intrathecal methotrexate prompting hydrocortisone to be added. Bone marrow biopsy done about 3 months later confirmed systemic relapse and cerebrospinal fluid showed persistence of malignant cells for which cranial radiation therapy was started. The patient was then hospitalized 2 months later with sepsis after administration of vincristine/prednisone and was noted to have changes in mental status characterized as increased boredom and fatigue. About a month later, patient was referred to hospice care but did not enroll. Increasing LDH to 2008 U/L was noted 2 months later at which time vincristine/prednisone were discontinued due to thrombocytopenia requiring platelet transfusions. Fludarabine was initiated about a month later without adverse effect. LDH remained elevated but stable at the time and uric acid remained within normal limits.

In the emergency department, his vital signs were within normal limits. Physical examination was notable for petechiae on the palette and oropharyngeal thrush. There was no apparent lymphadenopathy and neurological examination was unremarkable. Labs were significant for thrombocytopenia (platelet count=26,000/μL), anion gap elevated to 25, mild hypercalcemia, mild transaminitis, lactate increased to 14.2 mmol/L, LDH significantly increased to 4554 U/L, and trace ketones on urinalysis. Electrocardiogram showed no acute ischemic changes. 2-view chest x-ray was within normal limits.

Upon arrival to the hematology/oncology floor, patient was continued on intravenous fluids (normal saline). His extreme elevation in LDH with an upward trend over the past few months was thought to be due to progression of ALL. The reason for acute elevation to 4554 U/L on admission remained unclear. Tumor lysis syndrome was not felt to be contributing given lack of electrolyte abnormalities and uric acid found to be within normal limits. LDH improved to 2551 U/L with administration of normal saline prior to discharge. Patient was discharged with plan for close monitoring of his labs in the outpatient setting. Salvage chemotherapy with vincristine and prednisone was started shortly after discharge but was discontinued due to poor functional status and goals of care were shifted to comfort-focused care within a couple of weeks thereafter.

Profound lactic acidosis with gradually increasing anion gap in correlation with increasing LDH was thought to be secondary to type B lactic acidosis related to progressive ALL although the pathophysiologic mechanism for this is unknown. It was felt that type A lactic acidosis was clinically unlikely as patient remained without abdominal pain, hematochezia, signs or symptoms of ischemic disease, and no acute elevation in lactate or acidemia. The gradual rise of lactate and compensated pH as seen in this patient is not typical for type A lactic acidosis. Drug-induced lactic acidosis was also considered as patient reported compliance with metformin 500 mg by mouth

daily although there was low suspicion that this may be the cause of lactic acidosis given stable renal function (glomerular filtration rate = 89). It was, however, discontinued at the time of discharge in case it was contributing. As G6PD deficiency can also elicit type B lactic acidosis, atovaquone for Pneumocystis carinii pneumonia prophylaxis was discontinued although there was low suspicion for this as the cause of type B lactic acidosis given no prior documentation of G6PD deficiency and higher suspicion for other causes i.e., progression of ALL.

Overall, it was felt that the patient had advanced ALL with a poor prognosis which likely led to his poor PO intake, fatigue, lethargy and type B lactic acidosis. Emphasis was placed on hospice care and palliative efforts on an outpatient basis with the hope that patient might respond to salvage chemotherapy.

Discussion

The development of lactic acidosis associated with hematologic malignancy is rare but confers very poor prognosis. Type B lactic acidosis in malignancy was first reported in an acute leukemic patient in 1963 [4]. Another case was reported in Korea in 1999 in a patient with leukemia transformed from lymphoma [5]. In 2007, a case of type B lactic acidosis associated with thiamine deficiency was reported [6]. Approximately 67 total cases have been identified via review of literature [7]. Two more recent cases of ALL complicated by lactic acidosis were reported in 2010 in Japan [3] and Korea [8]. It is unfortunate that at this point the pathophysiologic process is poorly understood and there is little evidence to support various treatment options.

The data comes from case reports and case series of the few documented cases. The cause of type B lactic acidosis is likely multifactorial. There is some suggestion that its development is related to liver and/or kidney dysfunction, tumor cell overexpression of certain glycolytic enzymes and mitochondrial dysfunction, overexpression of TNF-alpha which results in reduced activity of pyruvate dehydrogenase, thiamine deficiency, and tumor lysis syndrome. [7] Liver and kidney dysfunction whether they be from tumor infiltration, ischemic damage, or other causes are thought to be two processes that contribute to the development of type B lactic acidosis as lactate is the end product of anaerobic metabolism and is converted to pyruvate and subsequently glucose by both the liver (90%) and the kidneys (10%) [9] via glycolysis. However, many patients with kidney and liver dysfunction do not develop severe lactic acidosis which suggests that there is likely a more complex process or processes responsible for the development of severe lactic acidosis. [7]

Another proposed mechanism relates to tumor cell overexpression of certain glycolytic enzymes and mitochondrial dysfunction. [10-11] Some tumor cells overexpress insulin-like growth factor-I and hexokinase which results in high rates of glycolysis and higher glucose levels, allowing for more rapid proliferation of cells. Despite the presence of oxygen, cancer cells often utilize anaerobic metabolism which results in significant production of lactate. [10] In addition, the presence of a dense compressing tumor mass or leukemic microemboli can impair tissue perfusion and cause ischemia which results in increased anaerobic glycolysis [12].

There is some suggestion that TNFα plays a role in the development of type B lactic acidosis. The thought is that it has multiple paracrine actions on tumor cells and affects mitochondrial function. Specifically, TNFα causes a reduction in the activity of pyruvate dehydrogenase and inhibits the cytochrome-dependent electron transport system which results in increased lactate levels in addition to having systemic effects that alter hepatic glucose metabolism. [13] However, hyperlacticacidemia itself has been shown to increase transcription of the gene that encodes TNFα in vitro [14]. Studies have shown decrease in elevated TNFα levels after treatment of newly diagnosed patients with leukemia and non-Hodgkin lymphoma with chemotherapy [15]. It is unclear whether increased TNFα production reflects the process of malignant disease or the host's defense against it as ongoing cell proliferation itself can result in both elevated lactate and TNFα levels. [14]

Thiamine deficiency is another possible mechanism that may trigger the development of type B lactic acidosis as thiamine is an important cofactor in the pyruvate dehydrogenase complex. Thiamine is necessary for the conversion of pyruvate into acetyl coenzyme A via pyruvate dehydrogenase. Hindrance of this pathway results in anaerobic metabolism and thereby results in production of lactate. This phenomenon has been reported in patients on total parenteral nutrition without vitamin supplementation although some of these patients also had malignancy. The acidosis in this situation was successfully reversed via addition of thiamine to the alimentation solution. [16] Furthermore, administration of methotrexate in chemotherapy regimens can result in the development type B lactic acidosis because it competes with thiamine transport systems and results in inhibition of pyruvate dehydrogenase and initiation of

anaerobic metabolism as described above. [10 & 17] Nucleoside reverse transcriptase inhibitors (NRTIs) used in the treatment of HIV have also been associated with the development of type B lactic acidosis due to mitochondrial dysfunction with aberrant glycolytic processes. Thiamine and riboflavin have been used to successfully treat this complication which suggests that vitamin deficiencies may be an important cofactor in the development of type B lactic acidosis in HIV patients. [18-21]

Finally, tumor lysis syndrome has been attributed to the development of type B lactic acidosis as well. The thought is that apoptosis of the tumor cells causes a loss in the mitochondrial membrane potential which results in the loss of mitochondrial function and leads to compensatory glycolysis with lactate formation and acidosis. [22]

In the few cases of type B lactic acidosis that have been identified, it appears that many of the patients who developed this phenomenon had bulky disease or large tumor burden. This suggests that these patients may have the highest risk for development of type B lactic acidosis. Many also had hepatic and renal involvement. [7] Although lactic acidosis is infrequently encountered in malignancies (though when it does occur it is most often associated with acute leukemias and high-grade lymphomas), it portends an extremely poor prognosis when it presents and therefore should be considered an oncologic emergency. The review of literature of type B lactic acidosis reveals that many cases had concomitant sepsis, anemia, surgical procedures, abnormal vital signs, or at least one vital sign indicative of systemic inflammatory response so it is difficult to discern how many of these cases were due to lymphoma or leukemia-associated lactic acidosis alone. [2]

The best treatment for patients with hematological malignancies who develop type B lactic acidosis is unclear at this time. Initiation of aggressive chemotherapy has been effective in a small number of patients. It is the only treatment modality that has consistently led to remission. Thus, treatment of the primary condition (i.e., cancer-directed therapy for leukemia/lymphoma) remains the mainstay of therapy. [8] The resolution of lactic acidosis occurred in 6 out of 7 of the 29 cases that responded to chemotherapy when reviewed by Chan et al. The lactic acidosis resolved in 5 of these 6 cases within 15 hours to 3 days and in the remaining case resolution was noted weeks after chemotherapy was introduced but within 2 days after salvage chemotherapy was initiated. [2]

Until chemotherapy takes effect to treat the underlying malignancy, both intravenous bicarbonate and hemodialysis have been used to control lactic acidosis although its use is controversial. Since severe acidosis can cause respiratory fatigue and hemodynamic instability, intravenous bicarbonate is often given to reverse the lactic acidosis. However, there are potential severe side effects to this therapy including hypervolemia and hypernatremia and it can even initially increase lactic acid production. [23-24] The postulated mechanism for this is that decreased oxygen delivery results in reduced PaO2 [25] and increased affinity of O2 to hemoglobin results from the increase in systemic pH due to intravenous bicarbonate infusion [26]. Of these same 29 cases reviewed by Chan et al., 20 received intravenous bicarbonate to counter lactic acidosis. 2 of these patients received bicarbonate without adjuvant chemotherapy and both did not survive more than days. Of the 7 patients who went into remission, 6 of them had received intravenous bicarbonate. There is limited data available regarding use of intravenous bicarbonate as it has not been formally studied. [2] In addition, renal replacement therapy (hemodialysis, peritoneal dialysis, hemofiltration) in such cases of malignancy-related lactic acidosis has been used in a few cases as a bridge until chemotherapy can be initiated to treat the underlying cause. [27] 2 of 3 such reported cases both died within 10 days of initiation of renal replacement therapy, suggesting unclear benefit. It appears to be clear that prompt diagnosis and early treatment of the underlying malignancy is the only way to achieve complete resolution of lactic acidosis in malignancy-related type B lactic acidosis. [2]

In our patient, it is likely that his elevated LDH and type B lactic acidosis were due to progression of his refractory acute lymphoblastic lymphoma. Other factors that could have contributed to its development include liver dysfunction as his LFTs were notable for a hepatotoxic pattern without prior history of liver disease. He was not treated with intravenous bicarbonate, thiamine, or renal replacement therapy because he remained asymptomatic despite such extreme elevations in LDH and severe lactic acidosis. Rather, he was started on salvage chemotherapy (vincristine and prednisone) to treat the underlying cause which was felt to be progression of his ALL. However, this was stopped after one cycle and goals of care were shifted to comfort care within weeks after discharge due to patient's poor performance status.

Conclusion

Overall, type B lactic acidosis appears to be a rare but severe and often lethal complication of hematological malignancies. The exact pathophysiology that governs its development still remains unclear although it appears to be multifactorial with a number of possible mechanisms postulated to describe its development as described above. Although rare, it is imperative that physicians be aware that it can manifest at the time of initial diagnosis or in the setting of recurrence/advanced malignancy. The mainstay of therapy remains prompt treatment of the underlying disease with chemotherapy as this has been the only therapy found to be effective in terms of long-term resolution of the lactic acidosis and remission of the hematological malignancy. A few cases have been noted to reach remission, but the majority of cases have been fatal. For this reason, further investigation regarding the pathophysiology of type B lactic acidosis in hematological malignancies is critical. In addition, early diagnosis and prompt treatment are imperative to prevent poor outcomes.

References

1. Luft D, Deichsel G, Schmülling RM, Stein W, Eggstein M. (1983). Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol 80(4): 484-489.v
2. Chan FH, Carl D, Lyckholm, LJ. (2009). Severe lactic acidosis in a patient with B-cell lymphoma: a case report and review of the literature. Case Rep Med: 1-7.
3. Chang H, Shuai X, Ma HB, Liu, T. (2010). A case report of acute lymphoblastic leukemia complicated by lactic acidosis. Int J Hematol 92(3): 538-541.
4. Scheerer PP, Pierre RV, Schwartz DL, Linman JW. (1964). Reed–Sternberg-Cell Leukemia and Lactic Acidosis: Unusual Manifestations of Hodgkin's Disease. N Engl J Med 270(6): 274-278.
5. Ma KA, Seo YJ, Kim SJ, Ahn SK, Kim MS, et al. (1999). Lactic acidosis associated with acute lymphoblastic leukemia. Korean J Nephrol 18: 505–509.
6. Byun SW, Choi SH, Park HG, Kim BJ, Kim EY, et al. (2007). A case of lactic acidosis caused by thiamine deficiency. Korean J Intern Med 73(4): 443-447.
7. Friedenberg AS, Brandoff DE, Schiffman FJ. (2007). Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review. Medicine 86(4): 225-232.
8. Lee HS, Kim HJ, Choi S, Kim CK, Lee NS, et. al. (2010). A case of type B lactic acidosis in acute leukemia. Yonsei Med J 51(3): 460-462.
9. Van der Beek A, de Meijer PHEM, Meinders AE. (2001). Lactic acidosis: pathophysiology, diagnosis and treatment. Neth J Med 58(3): 128-136.
10. Sillos EM, Shenep JL, Burghen GA, Pui CH, Behm FG, et. al. (2001). Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer 92(9): 2237-2246.
11. Thakur V, Sander G, Rab ST. (2001). Hodgkin's disease and lactic acidosis. Nephron 88(3): 276.
12. Block JB. (1974). Lactic acidosis in malignancy and observations on its possible pathogenesis. NYASA 230(1): 94-102.
13. Dürig J, Fiedler W, De Wit M, Steffen M, Hossfeld DK. (1996). Lactic acidosis and hypoglycemia in a patient with high-grade non-Hodgkin's lymphoma and elevated circulating TNF-α. Ann Hematol 72(2): 97-99.
14. Jensen JC, Buresh C, Norton JA. (1990). Lactic acidosis increases tumor necrosis factor secretion and transcription in vitro. J Surg Res 49(4): 350-353.
15. Abrahamsson J, Carlsson B, Mellander L. (1993). Tumor Necrosis Factor-alpha in Malignant Disease. Am J Pediatr Hematol Oncol 15: 364-364.
16. Svahn J, Schiaffino MC, Caruso U, Calvillo M, Minniti G, et. al. (2003). Severe lactic acidosis due to thiamine deficiency in a patient with B-cell leukemia/lymphoma on total parenteral nutrition during high-dose methotrexate therapy. J Pediatr Hematol Oncol 25(12): 965-968.
17. Zhao R, Gao F, Wang Y, Diaz GA, Gelb BD, et. al. (2001). Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 276(2): 1114-1118.
18. Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, et. al. (2001). Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. Int J STD AIDS 12(6): 407-409.
19. Dalton SD, Rahimi AR. (2001). Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis. AIDS Patient Care STDS 15(12): 611-614.
20. Monier PL, Wilcox R. (2004). Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults. Am J Med Sci 328: 48-56.
21. Shaer A, Rastegar A. (2000). Lactic acidosis in the setting of antiretroviral therapy for acquired immunodeficiency syndrome. A case report and review of literature. Am J Nephrol 20(4): 332-338.

22. Tiefenthaler M, Amberger A, Bacher N, Hartmann BL, Margreiter R, et. al. (2001). Increased lactate production follows loss of mitochondrial membrane potential during apoptosis of human leukaemia cells. Br J Haematol 114(3): 574-580.
23. Forsythe SM, Schmidt GA. (2000). Sodium bicarbonate for the treatment of lactic acidosis. Chest 117(1): 260-267.
24. Máttar JA, Weil MH, Shubin H, Stein L. (1974). Cardiac arrest in the critically ill: II. Hyperosmolal states following cardiac arrest. Am J Med 56(2): 162-168.
25. Bersin RM, Chatterjee K, Arieff AI. (1989). Metabolic and hemodynamic consequences of sodium bicarbonate administration in patients with heart disease. Am J Med 87(1): 7-14.
26. Bellingham AJ, Detter JC, Lenfant, C. (1971). Regulatory mechanisms of hemoglobin oxygen affinity in acidosis and alkalosis. J Clin Invest 50(3): 700-706.
27. Fall PJ, Szerlip HM. (2005). Lactic acidosis: from sour milk to septic shock. J Intensive Care Med 20(5): 255-271.